Investigating Hapten Clustering as a Strategy to Enhance Vaccines against Drugs of Abuse

被引:35
作者
Collins, Karen C.
Janda, Kim D. [1 ]
机构
[1] Scripps Res Inst, Skaggs Inst Chem Biol, WIRM, Dept Chem, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
SMOKING-CESSATION; NICOTINE VACCINE; IMMUNOGENICITY; ADAMANTANE; ANTIBODIES; IMMUNIZATION; CHEMISTRY; DENSITY; MODEL;
D O I
10.1021/bc500016k
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Vaccines for drugs of abuse have yet to achieve full clinical relevance, largely due to poor/inconsistent immune responses in patients. The use of multivalent scaffolding as a means to tailor drug-hapten density and clustering was examined in the context of drug-immune response modulation. A modular trivalent hapten containing a diglycine spacer, triAM1(Gly)(2), was synthesized and shown to elicit anti-nicotine antibodies at equivalent affinity and concentration to the monovalent AM1 analog, despite in this instance having a lower effective hapten density. Augmenting this data, the corresponding monovalent hapten AM1(Gly)(2) resulted in enhanced antibody affinity and concentration. Drug-hapten clustering represents a new vaccine paradigm, and, while examined only in the context of nicotine, it should be readily translatable to other drugs of abuse.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 34 条
[1]  
[Anonymous], WHO Report on the Global Tobacco Epidemic, 2008 - The MPOWER package
[2]  
[Anonymous], 2001, IMMUNOBIOLOGY IMMUNE
[3]  
Baum K., 1991, U. S. Patent, Patent No. [5017734 (A), 5017734]
[4]   Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit [J].
Boyaka, PN ;
Ohmura, M ;
Fujihashi, K ;
Koga, T ;
Yamamoto, M ;
Kweon, MN ;
Takeda, Y ;
Jackson, RJ ;
Kiyono, H ;
Yuki, Y ;
McGhee, JR .
JOURNAL OF IMMUNOLOGY, 2003, 170 (01) :454-462
[5]   Immunotherapy for cancer: synthetic carbohydrate-based vaccines [J].
Buskas, Therese ;
Thompson, Pamela ;
Boons, Geert-Jan .
CHEMICAL COMMUNICATIONS, 2009, (36) :5335-5349
[6]   Combined active and passive immunization against nicotine: Minimizing monoclonal antibody requirements using a target antibody concentration strategy [J].
Cornish, Katherine E. ;
Harris, Andrew C. ;
LeSage, Mark G. ;
Keyler, Dan E. ;
Burroughs, Danielle ;
Earley, Cathy ;
Pentel, Paul R. .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (11) :1809-1815
[7]   A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial [J].
Cornuz, Jacques ;
Zwahlen, Susanne ;
Jungi, Walter Felix ;
Osterwalder, Joseph ;
Klingler, Karl ;
van Melle, Guy ;
Bangala, Yolande ;
Guessous, Idris ;
Mueller, Philipp ;
Willers, Joerg ;
Maurer, Patrik ;
Bachmann, Martin F. ;
Cerny, Thomas .
PLOS ONE, 2008, 3 (06)
[8]  
CUSHMAN M, 1972, J ORG CHEM, V37, P1268, DOI 10.1021/jo00973a046
[9]  
DELIMARSKY RE, 1988, UKR KHIM ZH+, V54, P437
[10]   MOLECULAR DETERMINANTS OF IMMUNOGENICITY - IMMUNON MODEL OF IMMUNE-RESPONSE [J].
DINTZIS, HM ;
DINTZIS, RZ ;
VOGELSTEIN, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (10) :3671-3675